Quadrichemotherapy for advanced ovarian carcinoma

Margaret Anne Kessinger, J. F. Foley, H. M. Lemon

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In an effort to improve the length and rate of objective responses in patients with advanced ovarian carcinoma, a combination of four drugs was administered. Vincristine (10 μg/kg intravenously weekly), actinomycin D (500 μg intravenously weekly), oral methotrexate (1.25 mg daily) and oral cyclophosphamide (50 mg daily) were given to 25 evaluable patients with FIGO Stage III and IV ovarian carcinoma. After 12 weeks the vincristine and methotrexate were discontinued; cyclophosphamide and methotrexate were continued until disease progression was evident. Objective responses occurred in 56% of the patients. Toxicity was minimal. Patients not previously treated with radiotherapy or chemotherapy had a higher complete response rate (30%) than patients previously treated (13.3%). Mean length of complete response was 10.6+ months. The 1 year survival rate of these patients was 69.5% and the 5 year rate 22.7%. While the results are encouraging, single agent chemotherapy with an alkylating agent produces similar responses.

Original languageEnglish (US)
Pages (from-to)134-136
Number of pages3
JournalObstetrics and gynecology
Volume48
Issue number2
StatePublished - Dec 1 1976

Fingerprint

Carcinoma
Methotrexate
Vincristine
Cyclophosphamide
Drug Therapy
Alkylating Agents
Dactinomycin
Drug Combinations
Disease Progression
Radiotherapy
Survival Rate

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Kessinger, M. A., Foley, J. F., & Lemon, H. M. (1976). Quadrichemotherapy for advanced ovarian carcinoma. Obstetrics and gynecology, 48(2), 134-136.

Quadrichemotherapy for advanced ovarian carcinoma. / Kessinger, Margaret Anne; Foley, J. F.; Lemon, H. M.

In: Obstetrics and gynecology, Vol. 48, No. 2, 01.12.1976, p. 134-136.

Research output: Contribution to journalArticle

Kessinger, MA, Foley, JF & Lemon, HM 1976, 'Quadrichemotherapy for advanced ovarian carcinoma', Obstetrics and gynecology, vol. 48, no. 2, pp. 134-136.
Kessinger MA, Foley JF, Lemon HM. Quadrichemotherapy for advanced ovarian carcinoma. Obstetrics and gynecology. 1976 Dec 1;48(2):134-136.
Kessinger, Margaret Anne ; Foley, J. F. ; Lemon, H. M. / Quadrichemotherapy for advanced ovarian carcinoma. In: Obstetrics and gynecology. 1976 ; Vol. 48, No. 2. pp. 134-136.
@article{bcba60d213224b53be3d42d7100de0fc,
title = "Quadrichemotherapy for advanced ovarian carcinoma",
abstract = "In an effort to improve the length and rate of objective responses in patients with advanced ovarian carcinoma, a combination of four drugs was administered. Vincristine (10 μg/kg intravenously weekly), actinomycin D (500 μg intravenously weekly), oral methotrexate (1.25 mg daily) and oral cyclophosphamide (50 mg daily) were given to 25 evaluable patients with FIGO Stage III and IV ovarian carcinoma. After 12 weeks the vincristine and methotrexate were discontinued; cyclophosphamide and methotrexate were continued until disease progression was evident. Objective responses occurred in 56{\%} of the patients. Toxicity was minimal. Patients not previously treated with radiotherapy or chemotherapy had a higher complete response rate (30{\%}) than patients previously treated (13.3{\%}). Mean length of complete response was 10.6+ months. The 1 year survival rate of these patients was 69.5{\%} and the 5 year rate 22.7{\%}. While the results are encouraging, single agent chemotherapy with an alkylating agent produces similar responses.",
author = "Kessinger, {Margaret Anne} and Foley, {J. F.} and Lemon, {H. M.}",
year = "1976",
month = "12",
day = "1",
language = "English (US)",
volume = "48",
pages = "134--136",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Quadrichemotherapy for advanced ovarian carcinoma

AU - Kessinger, Margaret Anne

AU - Foley, J. F.

AU - Lemon, H. M.

PY - 1976/12/1

Y1 - 1976/12/1

N2 - In an effort to improve the length and rate of objective responses in patients with advanced ovarian carcinoma, a combination of four drugs was administered. Vincristine (10 μg/kg intravenously weekly), actinomycin D (500 μg intravenously weekly), oral methotrexate (1.25 mg daily) and oral cyclophosphamide (50 mg daily) were given to 25 evaluable patients with FIGO Stage III and IV ovarian carcinoma. After 12 weeks the vincristine and methotrexate were discontinued; cyclophosphamide and methotrexate were continued until disease progression was evident. Objective responses occurred in 56% of the patients. Toxicity was minimal. Patients not previously treated with radiotherapy or chemotherapy had a higher complete response rate (30%) than patients previously treated (13.3%). Mean length of complete response was 10.6+ months. The 1 year survival rate of these patients was 69.5% and the 5 year rate 22.7%. While the results are encouraging, single agent chemotherapy with an alkylating agent produces similar responses.

AB - In an effort to improve the length and rate of objective responses in patients with advanced ovarian carcinoma, a combination of four drugs was administered. Vincristine (10 μg/kg intravenously weekly), actinomycin D (500 μg intravenously weekly), oral methotrexate (1.25 mg daily) and oral cyclophosphamide (50 mg daily) were given to 25 evaluable patients with FIGO Stage III and IV ovarian carcinoma. After 12 weeks the vincristine and methotrexate were discontinued; cyclophosphamide and methotrexate were continued until disease progression was evident. Objective responses occurred in 56% of the patients. Toxicity was minimal. Patients not previously treated with radiotherapy or chemotherapy had a higher complete response rate (30%) than patients previously treated (13.3%). Mean length of complete response was 10.6+ months. The 1 year survival rate of these patients was 69.5% and the 5 year rate 22.7%. While the results are encouraging, single agent chemotherapy with an alkylating agent produces similar responses.

UR - http://www.scopus.com/inward/record.url?scp=0017196821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017196821&partnerID=8YFLogxK

M3 - Article

VL - 48

SP - 134

EP - 136

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 2

ER -